Home/Pipeline/HP-Betadex DPI Formulations

HP-Betadex DPI Formulations

Asthma, COPD

ClinicalActive

Key Facts

Indication

Asthma, COPD

Phase

Clinical

Status

Active

Company

Aquilon Pharmaceuticals

About Aquilon Pharmaceuticals

Aquilon Pharmaceuticals is a private, clinical-stage biotech leveraging its proprietary HP-Betadex excipient platform to revolutionize inhaled drug delivery. The company aims to enhance the pharmacology and lung deposition of drugs for respiratory diseases, with a pipeline progressing through clinical trials. With strong academic roots and recent €6 million refinancing, Aquilon is positioning for the commercial launch of its nasal product line while advancing its dry powder inhaler formulations.

View full company profile

Therapeutic Areas

Asthma COPD Nasal Conditions

Other Asthma, COPD Drugs

Drug	Company	Phase	Status
HBM9378 (SKB378/WIN378)	Harbour BioMed	Phase 1	Active (Greater China)
Generic Advair (Fluticasone/Salmeterol)	Lupin Limited	ANDA Filed/Approved	Active
Respiratory Inhalation Portfolio (Generic)	Cipla	ANDA Filed/Approved	Active
Wixela Inhub (Fluticasone/Salmeterol)	Viatris	Launched	Marketed (US, Authorized Generic)
QX008N	Qyuns Therapeutics	Phase 1	Active
RELVAR/BREO ELLIPTA	Innoviva	Commercial	Royalty Revenue Generating